Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever
- 31 August 2007
- journal article
- Published by Elsevier in Journal of Infection
- Vol. 55 (2) , 184-187
- https://doi.org/10.1016/j.jinf.2007.02.010
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Crimean-Congo haemorrhagic feverThe Lancet Infectious Diseases, 2006
- Thrombin activatable fibrinolysis inhibitor (TAFI)—How does thrombin regulate fibrinolysis?Annals of Medicine, 2006
- HISTORICAL SKETCH: The discovery of TAFIJournal of Thrombosis and Haemostasis, 2005
- Crimean?Congo hemorrhagic feverAntiviral Research, 2004
- Crimean-Congo Hemorrhagic Fever in TurkeyEmerging Infectious Diseases, 2004
- New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)Seminars in Hematology, 2004
- Pathogenesis of Ebola Hemorrhagic Fever in Primate ModelsThe American Journal of Pathology, 2003
- Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the Interface between Coagulation and FibrinolysisPathophysiology of Haemostasis and Thrombosis, 2003
- Clinical features of crimean-congo haemorrhagic fever in the united arab emiratesInfection, 1997
- The Clinical Pathology of Crimean-Congo Hemorrhagic FeverClinical Infectious Diseases, 1989